INVENTIVA (EPA:IVA) | WebDisclosure

PRESS RELEASE

published on 10/14/2025 at 22:00, 5 months 10 days ago

Inventiva annonce la mise en place d’un nouveau programme « At-The-Market » (ATM)
Inventiva lance un nouveau programme de financement At-the-Market (ATM) pour une levée de fonds jusqu'c 100 millions de dollars, dans le but de soutenir le développement de thérapies contre la stéatohépatite

Financement Inventiva Stéatohépatite Thérapies ATM
PRESS RELEASE

published on 10/14/2025 at 22:00, 5 months 10 days ago

Inventiva Announces the Implementation of a New ATM Program
Inventiva implements new ATM program, files Registration Statement with the SEC for up to $100 million aggregate gross sales proceeds. Proceeds to fund research and development, working capital, and corporate purposes

Biopharmaceutical SEC Registration Statement Inventiva ATM Program
BRIEF

published on 10/07/2025 at 22:05, 5 months 17 days ago

Inventiva at Liver Meeting 2025: Key Presentations on Lanifibranor

Digital Pathology Inventiva MASH Lanifibranor Liver Meeting 2025
BRIEF

published on 10/07/2025 at 22:05, 5 months 17 days ago

Inventiva au Liver Meeting 2025 : Présentations Clés sur Lanifibranor

Pathologie Numérique Inventiva MASH Lanifibranor Liver Meeting 2025
PRESS RELEASE

published on 10/07/2025 at 22:00, 5 months 17 days ago

Inventiva présentera plusieurs abstracts lors du congrès AASLD The Liver Meeting® 2025
Inventiva présentera plusieurs abstracts au congrès AASLD The Liver Meeting® 2025. Présentation d'une comparaison histologie numérique sur lame biopsies NATiV3 et pathologie numérique de lanifibranor préclinique

Pathologie Numérique Inventiva Lanifibranor AASLD The Liver Meeting 2025 Histologie Numérique
PRESS RELEASE

published on 10/07/2025 at 22:00, 5 months 17 days ago

Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
Inventiva to present multiple abstracts at AASLD The Liver Meeting® 2025 showcasing digital pathology data and therapeutic benefits of lanifibranor in MASH treatment. Visit booth #745 for more

Digital Pathology Inventiva MASH Lanifibranor AASLD The Liver Meeting
BRIEF

published on 10/01/2025 at 08:35, 5 months 24 days ago

Andrew Obenshain Appointed as CEO of Inventiva

Leadership Transition Drug Development Inventiva MASH Treatment Andrew Obenshain
BRIEF

published on 10/01/2025 at 08:35, 5 months 24 days ago

Andrew Obenshain nommé PDG d'Inventiva

Transition De Leadership Développement De Médicaments Inventiva Traitement MASH André Obenshain
PRESS RELEASE

published on 10/01/2025 at 08:30, 5 months 24 days ago

Inventiva Appoints Andrew Obenshain as Chief Executive Officer
Inventiva appoints Andrew Obenshain as Chief Executive Officer, succeeding Frédéric Cren, to lead company's growth and prepare for potential commercialization in the United States

Chief Executive Officer Inventiva MASH Frédéric Cren Andrew Obenshain
PRESS RELEASE

published on 10/01/2025 at 08:30, 5 months 24 days ago

Inventiva annonce la nomination d’Andrew Obenshain au poste de Directeur Général
Inventiva annonce la nomination d'Andrew Obenshain au poste de Directeur Général, marquant une transition de leadership stratégique pour la société biopharmaceutique spécialisée dans le traitement de la MASH

Directeur Général Transition De Leadership Inventiva MASH Andrew Obenshain

Published on 03/25/2026 at 19:15, 2 hours 24 minutes ago

Gemina Laboratories Ltd. Announces Delisting from the CSE
Published on 03/25/2026 at 13:30, 8 hours 9 minutes ago

Prince Silver Files NI 43-101 Technical Report for Its Stampede Gap Porphyry Copper-Gold-Molybdenum Project in Nevada
Published on 03/25/2026 at 13:30, 8 hours 9 minutes ago

Triera Biosciences - a Zentek Company - Launches Contract Research Organization Services for Custom Aptamer Discovery, Biosensor Enablement, and Machine-Learning Classification
Published on 03/25/2026 at 13:30, 8 hours 9 minutes ago

Strategic Metals Closes Project Sale
Published on 03/25/2026 at 13:25, 8 hours 14 minutes ago

Predictiv AI Expands Active Deployment of CloudRep.ai Across Healthcare, Retail, Real Estate, Travel and Global Markets

View all ACCESSWIRE

Published on 03/25/2026 at 20:00, 1 hour 39 minutes ago

Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
Published on 03/25/2026 at 19:41, 1 hour 58 minutes ago

EQS-Adhoc: STRATEC POSTS IMPAIRMENTS, REPORTS PRELIMINARY RESULTS FOR 2025, AND OFFERS GUIDANCE FOR 2026
Published on 03/25/2026 at 19:30, 2 hours 9 minutes ago

AIXTRON to expand global footprint with new plant in Malaysia
Published on 03/25/2026 at 19:26, 2 hours 13 minutes ago

EQS-Adhoc: AIXTRON SE to expand global footprint with new plant in Malaysia
Published on 03/25/2026 at 18:40, 2 hours 59 minutes ago

TULKUBASH AND KYZYLTASH MINING ASSETS: DECLARATION FROM A GROUP OF INVESTORS

View all EQS

Published on 03/25/2026 at 18:53, 2 hours 45 minutes ago

CIS - Transfert Contrat de Liquidité Portzamparc - 25.03.2026
Published on 03/25/2026 at 18:53, 2 hours 46 minutes ago

LNA SANTE : 2025 Annual Results
Published on 03/25/2026 at 18:31, 3 hours 8 minutes ago

Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 18:31, 3 hours 8 minutes ago

Performance soutenue des Investissements et déploiement actif de la stratégie
Published on 03/25/2026 at 18:06, 3 hours 33 minutes ago

LNA SANTE : Résultats Annuels 2025

View all LES ECHOS COMFI WIRE

News